|
May 20
|
BMO Capital Maintains Buy Rating on Pfizer (PFE) Stock
|
|
May 20
|
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
|
|
May 20
|
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
|
|
May 20
|
Pfizer Strikes up to $6.05 Billion Licensing Deal for 3SBio's Cancer Drug Candidate
|
|
May 20
|
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
|
|
May 20
|
Pfizer buys into PD-1/VEGF competition with 3SBio deal
|
|
May 20
|
Pfizer signs global licensing deal with 3SBio for bispecific antibody
|
|
May 20
|
Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio
|
|
May 20
|
Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake
|